ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Drug toxicity"

  • Abstract Number: 0461 • ACR Convergence 2022

    The Effects of Daily Prednisone and Tocilizumab on Hemoglobin A1c During the Treatment of Giant Cell Arteritis

    Naomi Patel1, Veronica Tozzo2, John Higgins2 and John Stone3, 1Massachusetts General Hospital, Sale Creek, TN, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: Hemoglobin A1c (HbA1c) is used clinically to estimate patients' average blood glucose over the preceding few months and is affected by glycemic as well…
  • Abstract Number: 1283 • ACR Convergence 2022

    Frequency of Checking Creatine Kinase in Patients on Statins with Elevated Transaminase for Early Detection of Statin Induced Myopathy

    ANJALI NIDHAAN, Andrei Hastings, david gonzalez, rajshri joshi, nathan gilbert and carolyn o'connor, Cleveland Clinic Akron General, Akron, OH

    Background/Purpose: Some of the most commonly reported side effects of statins (widely used lipid lowering agents) are muscle injury (incidence ranging from 0.1-20% based on…
  • Abstract Number: 0653 • ACR Convergence 2022

    JAK Inhibitors Counteract Cellular Toxicity of Hydroxychloroquine in Vitro

    Hiroshi Kajiyama1, Yoshimi Aizaki2, Hiroaki Yazawa3, Kazuhiro Yokota3, Yasuto Araki2, Yuji Akiyama2 and Toshihide Mimura4, 1Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Yokohama, Japan, 2Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma Saitama, Japan, 3Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma Saitama, 4Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan

    Background/Purpose: Hydroxychloroquine (HCQ) is an anti-malarial medicine and an immunomodulator to treat autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clinical…
  • Abstract Number: 1616 • ACR Convergence 2022

    Drug Use and Pregnancy Outcomes in Pregnant Women with Systemic Vasculitis: A Nation Wide Cohort Study

    Camille Mettler1, Nathanaël Beeker2, Mathis Collier2, Veronique Le Guern3, Benjamin Terrier4 and Laurent Chouchana5, 1Department of Internal Medicine, National Referral Center for Rare Systemic and Autoimmune Diseases, Cochin Hospital, Paris, France, 2Unité de Recherche clinique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France, 3Hôpital Cochin, Paris, France, 4National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 5Pharmacology department, Centre Régional de Pharmacovigilance, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France

    Background/Purpose: Women of childbearing age are rarely affected by systemic vasculitis (SV), explaining the lack of solid data regarding pregnancy in these patients. The objective…
  • Abstract Number: 0726 • ACR Convergence 2022

    Optimizing Laboratory Medication Safety Monitoring in Patients with JIA to Advance Value-based Care

    Julia Harris1, Leslie Favier2, Emily Fox3, Michael Holland3, Cara Hoffart3, Maria Ibarra3, Jordan Jones3, Luke Harris1 and Ashley Cooper3, 1Children's Mercy Kansas City, Overland Park, KS, 2Children's Mercy Kansas City, Leawood, KS, 3Children's Mercy Kansas City, Kansas City, MO

    Background/Purpose: Most children with juvenile idiopathic arthritis (JIA) are treated with medications that require medication safety monitoring labs. Recommended laboratory testing includes a creatinine level.…
  • Abstract Number: 1674 • ACR Convergence 2022

    In Utero Exposure to Hydroxychloroquine Does Not Associate with Ocular Toxicity as Assessed by Optical Coherence Tomography Five Years After Birth

    Peter Izmirly1, Mala Masson2, Michael Marmor3, Noel Zahr4, Nathalie Costedoat-Chalumeau5 and Jill Buyon1, 1NYU Grossman School of Medicine, New York, NY, 2NYU Langone Medical Center- Division of Rheumatology, New York, NY, 3Stanford University, Stanford, CA, 4Pitié-Salpêtrière Hospital, Paris, France, 5Inserm DR Paris 5, Paris, France

    Background/Purpose: The preventive approach to congenital heart block with hydroxychloroquine (HCQ) [PATCH] study supported the efficacy of HCQ to reduce the recurrence rate of cardiac…
  • Abstract Number: 0757 • ACR Convergence 2022

    Safety and Effectiveness of Immune Checkpoint Inhibitors Combination versus Single Agent Therapy in Patients with Pre-existing Autoimmune Diseases

    Pankti Reid1, Sabina Sandigursky2, Maria A. Lopez-Olivo3, Juhee Song4, Houssein Safa5, Samuel Cytryn6, Maryam Buni7, Anna Pavlick8, Michelle Krogsgaard, PhD9, Osama Abu-Shawer10, Mehmet Altan11, Jeffrey Weber12, Maria Suarez-Almazor13, Adi Diab14 and Noha Abdel-Wahab14, 1University of Chicago Medical Center, Chicago, IL, 2NYU Langone Health, New York, NY, 3The University of Texas, MD Anderson Cancer Center, Houston, TX, 4The University of Texas MD Anderson Cancer Center, Houston, TX, 5Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 6Memorial Sloan Kettering Cancer Center, New York, NY, 7MD Anderson Cancer Center, Bellaire, TX, 8Medical Oncology, Weill Cornell Medical Center, New York, NY, 9Perlmutter Cancer Center, Department of Pathology, NYU Langone Health, New York, NY, 10Cleveland Clinic Foundation, Cleveland, OH, 11Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 12NYU Langone Medical Center, Laura and Isaac Perlmutter Cancer Center, New York, NY, 13MD Anderson Cancer Center, Houston, TX, 14UT MD Anderson Cancer Center, Houston, TX

    Background/Purpose: Treatment with a combination of immune checkpoint inhibitors (ICI) has promising outcomes in many tumor types but carries higher adverse event risk than ICI…
  • Abstract Number: 1886 • ACR Convergence 2022

    Statin-induced Immune-mediated Miopathy: Treatment with Glucocorticoid-free Protocols and Role of Muscle Biopsy in the Follow-up

    David Martínez-López1, Piotr Szczęsny2, Inger Nennesmo3, Karina Gheorghe4, Antonella Notarnicola5, Helene Alexanderson6, Ingrid Lundberg7 and Maryam Dastmalchi8, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland. Department of Neurology, Medical University of Warsaw, Warsaw, Poland, 3Department of Pathology, Karolinska University Hospital,Pathology, Karolinska University Hospital., Stockholm, Sweden, 4Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet. Rheumatology, Karolinska University Hospital Stockholm, Sweden. Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 5Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 6Karolinska Institutet, Stockholm, Sweden, 7Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, 8Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: Statin-induced immune mediated necrotizing myopathy (IMNM) is a recently identified autoimmune condition associated with anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) antibodies, characterized by progressive muscle weakness leading…
  • Abstract Number: 0771 • ACR Convergence 2022

    The Use of a bDMARD or tsDMARD for the Management of Rheumatic irAE Under Checkpoint Inhibitors: An Observational Study

    Fanny De La Fuente1, Rakiba Belkhir2, Julien Henry3, Chi Duc Nguyen4, Thao Pham5, Vincent GERMAIN6, Pierre-Edouard Gavand7, Céline Labadie1, Claire Brière8, Ambre Lauret8, Thierry Cardon9, Gaël Mouterde10, Isabelle Bonnet11, Léa Rouxel12, Marie Truchetet1, Thierry schaeverbeke13, Christophe Richez14 and Marie Kostine15, 1Bordeaux University Hospital, Bordeaux, France, 2Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, 3Department of Rheumatology, University Paris-Saclay, Hospital Bicêtre, Le Plessis Robinson, Ile-de-France, France, 4Bethune Hospital, Bethune, France, 5Aix-Marseille univ, APHM, Marseille, France, 6Pau Hospital, Rheumatology, Pau, France, Pau, France, 7Rhena Clinic, Strasbourg, France, 8Intercommunal Creteil Hospital, Créteil, France, 9Lille University Hospital, Lille, France, 10Lapeyronie Hospital, Montpellier, France, 11University Paris-Saclay, Hospital Bicêtre, Bicêtre, France, 12Arcachon Hospital, Arcachon, France, 13CHU de Bordeaux, Bordeaux, France, 14Université de Bordeaux, Bordeaux, France, 15Pellegrin Hospital, University Hospital of Bordeaux, Rheumatology, Bordeaux, France

    Background/Purpose: Rheumatic immune related adverse events (irAEs) are observed in about 5 to 10% of cancer patients receiving checkpoint inhibitors (ICIs), with inflammatory arthritis (IA)…
  • Abstract Number: 2147 • ACR Convergence 2022

    Cumulative Dose and Exposure Time to Methotrexate Were Not Shown to Be Predictors of Hepatic Fibrosis by Elastography – A Monocentric Cohort Study

    Filipe Pinheiro1, Rui Gaspar2, Bruno Fernandes3, Armando Peixoto2, Guilherme Macedo2 and Iva Brito4, 1Rheumatology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, 2Gastroenterology Deparment, Centro Hospitalar e Universitário de São João, Porto, Portugal, 3Rheumatology Deparment, Centro Hospitalar e Universitário de São João, Porto, Portugal, 4Pediatric and Young Adult Rheumatology Unit, Centro Hospitalar Universitário de São João, Porto, Portugal

    Background/Purpose: Methotrexate is an immunomodulatory agentu sed in several inflammatory diseases, such as rheumatoid arthritis (RA), spondyloarthritis (SpA) or inflammatory bowel disease (IBD). Despite being…
  • Abstract Number: 1517 • ACR Convergence 2021

    Prevalence of Autoantibodies in Patients with Melanoma Who Develop Rheumatic Immune Related Adverse Events During Treatment with Immune Checkpoint Blockade

    Sophia Weinmann1, Amanda Eudy2 and David Pisetsky1, 1Duke University Medical Center, Durham, NC, 2Duke University, Durham, NC

    Background/Purpose: Patients with malignancy who develop rheumatic immune related adverse events (IRAEs) during immune checkpoint blockade (ICB) are commonly autoantibody negative. The change from chemotherapy…
  • Abstract Number: 1518 • ACR Convergence 2021

    Elucidating Activated Osteoarthritis as an Emerging Immune Checkpoint Inhibitor Toxicity: A Descriptive Observational Study

    Pankti Reid1, David Liew2, Rajshi Akruwala3, Anne Bass4 and Karmela Kim Chan5, 1University of Chicago Medical Center, Chicago, IL, 2Austin Health, Heidelberg, Australia, 3SUNY Downstate Health Sciences University College of Medicine, Brooklyn, NY, 4Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 5Hospital for Special Surgery, New York, NY

    Background/Purpose: Immune checkpoint inhibitors (ICIs) are a type of immunotherapy used for cancer management. ICI toxicities can challenge the ability to safely continue ICI therapy…
  • Abstract Number: 1522 • ACR Convergence 2021

    Potential Predictors of Persistence in Immune Check Point Inhibitor Induced Arthritis

    Anu Desai1, Lakshmi Priya Shadananan1, Adam Croft2, Lalit Pallan1, Neil Steven3 and Benjamin Fisher4, 1University of Birmingham, Birmingham, United Kingdom, 2University of Birmingham, Halesowen, United Kingdom, 3Institute of Immunology and Immunotherapy/University of Birmingham, Birmingham, United Kingdom, 4Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

    Background/Purpose: Immune Check Point Inhibitors (ICIs) are widely used in Oncology and are associated with multiple autoimmune and systemic inflammatory reactions called immune-related adverse events.…
  • Abstract Number: 1629 • ACR Convergence 2021

    Effect of Drug Withdrawal on Interleukin-1 or Interleukin-6 Inhibitor Associated Diffuse Lung Disease

    Vivian Saper1, Sampath Prahalad2, Scott Canna3, Rabheh Abdul-Aziz4, Marcela Alvarez5, Catherine Bingham6, Brigitte Bader-Meunier7, Imelda Balboni8, Roberta Berard9, Roxana Bolaria10, Alexis Boneparth11, Alicia Casey12, Elaine Cassidy13, Joyce C. Chang14, Michal Cidon15, Kathleen Collins16, Aileen M. Dickenson17, Graciela Espada5, Martha Fishman12, Elaine Flanagan18, Timothy Hahn19, Ankur K. Jindal20, Ozgur Kasapcopur21, Marisa Klein-Gitelman22, Timothy Klouda12, Mikhail Kostik23, Carol Lake24, Mariana Marques25, Michael Ombrello26, Karen Onel27, Omkar Phadke28, Angelo Ravelli29, Adam Reinhardt30, Amanda D. Robinson31, Kelly Rouster-Stevens32, Nadine Saad27, Grant Schulert33, Susan Shenoi34, Cory Stingl14, Anjali Sura35, Melissa Tesher36, Jessica Tibaldi37, Kathryn Torok38, Cathy Tsin39, Natalia Vasquez-Canizares40, D. Sofia Villacis-Nunez41, Ben Whitehead42, Holly Wobma12, Lawrence Zemel43 and Elizabeth Mellins1, 1Stanford University, Stanford, CA, 2Emory + Children's Pediatric Institute, Atlanta, GA, 3Children's Hospital of Philadelphia, Philadelphia, PA, 4University at Buffalo, Buffalo, NY, 5Hospital de Niños Dr Ricardo Gutierrez, Buenos Aires, Argentina, 6Penn State Children's Hospital, Allentown, PA, 7Pediatric Immuno-hematology, Necker Hospital, APHP, Paris, France, 8Stanford University, Palo Alto, CA, 9London Health Sciences Centre, London, ON, Canada, 10Self, Victoria, BC, Canada, 11Columbia University Medical Center, New York, NY, 12Boston Children's Hospital, Boston, MA, 13University of Pittsburgh Medical Center Medical Education, Pittsburgh, PA, 14Children's Hospital of Phildelphia, Philadelphia, PA, 15Children's Hospital Los Angeles, Los Angeles, CA, 16LeBonheur Children's Hospital, Memphis, TN, 17Children's Hospital of Los Angeles, Los Angeles, CA, 18Emory University and Children's Healthcare of Atlanta, Atlanta, GA, 19Penn State Childrens Hospital, Hershey, PA, 20Postgraduate Institute of Medical Education and Research, Chandigarh, India, 21Istanbul University-Cerrahpasa, Cerrahpasa Medical School, İstanbul, Turkey, 22Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 23Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, 24National Institutes of Health, Gaithersburg, MD, 25UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, 26National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 27Hospital for Special Surgery, New York, NY, 28EMORY, Atlanta, GA, 29Istituto Giannina Gaslini, Genoa, Italy, 30Boys Town National Research Hospital, Omaha, NE, 31UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, 32Emory University/Children's Healthcare of Atlanta, Atlanta, GA, 33Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 34Seattle Children's Hospital, Seattle, WA, 35SUNY Upstate Medical University, Syracuse, NY, 36University of Chicago, Chicago, IL, 37IRCSS Istituto G. Gaslini University of Genoa, Genoa, Italy, 38University of Pittsburgh, Pittsburgh, PA, 39Stanford University, Stanford, 40Children's Hospital at Montefiore, Bronx, NY, 41Children's Healthcare of Atlanta - Emory University, Atlanta, GA, 42Queensland Children's Hospital, Brisbane, Australia, 43CCMC, Hartford, CT

    Background/Purpose: Severe delayed hypersensitivity reactions (DHR) are under-recognized in inflammatory conditions, particularly drug reaction with eosinophilia and systemic symptoms (DRESS). Previous work has shown this…
  • Abstract Number: 0116 • ACR Convergence 2021

    COVID-19 mRNA Vaccine Side Effects Among Individuals with Rheumatic Disease

    Kaleb Michaud1, Adam Cornish2, Alison Freifeld1, Patricia Katz3 and Kristin Wipfler2, 1University of Nebraska Medical Center, Omaha, NE, 2FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 3University of California San Francisco, San Francisco, CA

    Background/Purpose: Over 135 million Americans were fully vaccinated to COVID-19 by June 2021, yet there was a paucity of data on side effects for those…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences